Kininogens are antithrombotic proteins in vivo

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 9, 1999, Pages 2245-2250

  Colman, Robert W ^a   White, John V ^a   Scovell, Sherry ^a   Stadnicki, Antoni ^a   Sartor, R B ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antithrombotic; Arterial thrombosis; Fibrinolysis; Kininogens; Rats

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; FIBRINOGEN; KININOGEN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE ACTIVATION;

EID: 0032877560     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.9.2245     Document Type: Article

References (41)

1. Roche e Silva M, Beraldo WT, Rosenfeld G. Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. Am J Physiol. 1949;150:261-272.
2. Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait: human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest. 1975;56:1650-1662.
3. Takagaki Y, Kitamura N, Nakanishi S. Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens: primary structures of two human prekininogens. J Biol Chem. 1985;260:8601-8609.
4. Schmaier AH, Bradford H, Silver LD, Farber A, Scott CF, Schutsky D, Colman RW. High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest. 1986;77:1565-1573.
5. Kunapuli SP, Bradford HN, Jameson BA, DeLa Cadena RA, Rick L, Wassell RP, Colman RW. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 domain 3 in the heavy chain of high molecular weight kininogen. J Biol Chem. 1996;271: 11228-11234.
6. Yung LL, Lim F, Khan MMH, Kunapuli SP, Rick L, Colman RW, Cooper SL. Neutrophil adhesion on surfaces preadsorbed with high molecular weight kininogen under well-defined flow conditions. Immunopharmacology. 1996;32:19-23.
7. Lin Y, Harris RB, Yan W, McCrae KR, Zhang H, Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood. 1997;90:690-697.
8. Puri RN, Zhou FX, Bradford H, Hu CJ, Colman RF, Colman RW. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain. Arch Biochem Biophys. 1989;271: 346-358.
9. Puri RN, Zhou F, Hu CJ, Colman RF, Colman RW. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood. 1991;77:500-507.
10. Gustafson EJ, Lukasiewicz H, Wachtfogel YT, Norton KJ, Schmaier AH, Niewiarowski S, Colman RW. High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J Cell Biol. 1989;109:377-387.
11. Wachtfogel YT, DeLa Cadena RA, Kunapuli SP, Rick L, Miller M, Schultze RL, Altieri DC, Edgington TS, Colman RW. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem. 1994;269: 19307-19312.
12. Hayashi I, Hoshiko S, Makabe O, Oh-ishi S. A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of brown Norway Katholiek rats. J Biol Chem. 1993;268:17219-17224.
13. Scott CF. Determination of antithrombin III (AT-III) using the Coatest Antithrombin Kit and a microplate system. Ann N Y Acad Sci. 1986;485: 443-444.
14. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimung des Fibrinogens. Acta Hematol. 1957;17:237-246.
15. Quick RJ. The assay and properties of labile factor (factor V). J Clin Pathol. (London) 1960;13:457.
16. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961;36:212-219.
17. Hawiger J, Niewiarowski S, Gurewich V, Thomas DP. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test. J Lab Clin Med. 1970;75:93-108.
18. Belcher PR, Drake-Holland AJ, Hynd JW, Noble MI. Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog. Clin Sci. 1996; 90:363-368.
19. Gomoll AW, Schumacher WA, Ogletree ML. Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function. Pharmacology. 1995;50:92-110.
20. Sullivan TR Jr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell TF Jr, Mendelsohn ME. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest. 1995;96:2482-2488.
21. Bradford HN, Schmaier AH, Colman RW. Kinetics of inhibition of platelet calpain II by human kininogens. Biochem J. 1990;270:83-90.
22. Saido T, Suzuki H, Yamazaki H, Tanoue K, Suzuki K. In situ capture of m-calpain activation of platelets. J Biol Chem. 1993;268:7422-7426.
23. Schmaier AH, Bradford HN, Lundberg D, Farber A, Colman RW. Membrane expression of platelet calpain. Blood. 1990;75:1273-1281.
24. Puri RN, Matsueda R, Umeyama H, Bradford HN, Colman RW. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine. Biochem Biophys Res Commun. 1989;162:1017-1024.
25. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2+3 of the urokinase receptor. J Clin Invest. 1997;100:1481-1487.
26. Mandle R Jr, Colman RW, Kaplan AP. Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976;73:4179-4183.
27. Lenich C, Pannell R, Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost. 1995;74:698-703.
28. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1983;66:835-839.
29. Sheikh IA, Kaplan AP. Studies of the digestion of bradykinin. Lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme. Biochem Pharmacol. 1986;35:1951-1956.
30. Hasan AAK, Amenta S, Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of a-thrombin-induced platelet activation. Circulation. 1996;94:517-528.
31. Bradford HN, DeLa Cadena RA, Kunapuli SP, Dong JF, Lopez JA, Colman RW. Human kininogens regulate thrombin binding to platelets through the GPIb-IX-V complex. Blood. 1997;90:1508-1515.
32. Joseph K, Bahou W, Kaplan AP. Evidence that the zinc-dependent platelet binding protein of factor XII and high molecular weight kininogen is glycoprotein Ib. J Invest Med. 1997;45:267A. Abstract.
33. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore). 1983;62:248-255.
34. Mannhalter C, Fisher M, Hopmeier P, Deutch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis. 1987;1:259-263.
35. Lammle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency: a study on 74 subjects from 14 Swiss families. Thromb Haemost. 1991;65:117-121.
36. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost. 1992;68:285-290.
37. von Kanel R, Wuillemin WA, Furlan M, Lammle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis, 1992;3:555-561.
38. Jespersen J, Munkvad S, Pedersen OD, Gram J, Kluft C. Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases. Ann N Y Acad Sci. 1992;667:454-456.
39. Munkvad S, Jespersen J, Gram J, Kluft C. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J Am Coll Cardiol. 1991;17:957-962.
40. Schmidt B. The etiology, diagnosis and treatment of thrombocic disorders in newborn infants: a call for international and multi-institutional studies. Semin Perinatol. 1997;21:86-89.
41. Roy M, Schmidt B. Neonatal thrombosis: are we doing the right studies? Semin Thromb Hemost. 1995;21:313-316.